Gilead Sciences Portfolio Concentration: Heavy Healthcare Exposure
This analysis details Gilead Sciences' highly concentrated portfolio as of June 30, 2026.
As of June 30, 2026, the investment profile of Gilead Sciences Inc., a major player in the biopharmaceutical sector, shows significant concentration within its holdings. The portfolio is dominated by positions primarily linked to other companies operating in the Healthcare industry.
According to available data, Gilead Sciences holds five distinct stocks across various sectors, but their allocation heavily favors one field. The Healthcare sector accounts for 100% of the portfolio's total value as reported by InsiderSet on that date.
The largest position in this Healthcare-focused portfolio belongs to Arcus Biosciences Inc. (RCUS), representing approximately 58.76% of the total portfolio value and allocation. This substantial stake underscores a significant exposure to advancements in therapeutic development.
Another major holding is Lakefront Biotherapeutics Inc. (GLPG), which holds about 30.34% of the portfolio allocation and contributes significantly to its total value. This further highlights Gilead's commitment to investing in other biotech entities.
Assembly Biosciences Inc. (ASMB) is also a key component, holding roughly 8.3% allocation as per InsiderSet data. Notably, this position saw an increase of about 10.47% in shares compared to the previous period, indicating active investment activity focused within the Healthcare space.
The remaining allocations are smaller but still concentrated in Healthcare: Kyverna Therapeutics Inc. (KYTX) at approximately 2.23%, and Xilio Therapeutics Inc. (XLO) contributing about 0.38%. This indicates that Gilead Sciences' investment strategy, reflected on their portfolio as of June 30, 2026, is highly focused within the Healthcare sector.
In summary, InsiderSet data reveals a very concentrated portfolio for Gilead Sciences Inc., with all assets invested in Healthcare companies. The top three holdings alone account for nearly all (100%) of the portfolio value, emphasizing exposure to specific biopharmaceutical advancements and potentially limiting diversification benefits.